
Bristol Myers’ sNDA for Sotyktu in Psoriatic Arthritis Accepted in Four Global Regions
Bristol Myers Squibb’s Sotyktu Makes Global Regulatory Progress for Psoriatic Arthritis as FDA Accepts sNDA for Review In a major development for immunology-focused therapeutics, Bristol Myers Squibb (NYSE: BMY) has…












